Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: A meta-analysis of five prospective trials by the german CLL study group (GCLLSG)

Haematologica

Volumn 100, Issue 11, 2015, Pages 1451-1459

  Cramer, Paula ^a   Isfort, Susanne ^a,b   Bahlo, Jasmin ^a   Stilgenbauer, Stephan ^c   Döhner, Hartmut ^c   Bergmann, Manuela ^d   Stauch, Martina ^e   Kneba, Michael ^f   Lange, Elisabeth ^g   Langerbeins, Petra ^a   Pflug, Natali ^a   Kovacs, Gabor ^a   Goede, Valentin ^a   Fink, Anna Maria ^a   Elter, Thomas ^a   Fischer, Kirsten ^a   Wendtner, Clemens Martin ^a,d   Hallek, Michael ^a   Eichhorst, Barbara ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d Klinikum Schwabing   (Germany)

^e Specialized Practice for Hematology and Oncology and Day Hospital   (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g Hamm Protestant Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTHRACYCLINE; BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; MITOXANTRONE; OBINUTUZUMAB; OFATUMUMAB; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; PREDNISOLONE;

ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; META ANALYSIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; TREATMENT OUTCOME; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; PREDNISOLONE; PROSPECTIVE STUDIES; RITUXIMAB; VINCRISTINE;

EID: 84946222445     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.124693     Document Type: Article

References (27)

1. Kristinsson SY, Dickman PW, Wilson WH, Caporaso N, Bjorkholm M, Landgren O. Improved survival in chronic lymphocytic leukemia in the past decade: a populationbased study including 11,179 patients diagnosed between 1973-2003 in Sweden. Haematologica. 2009;94(9):1259-1265.
2. Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood. 2009;114(16):3382-3391.
3. Han T, Ezdinli EZ, Shimaoka K, Desai DV. Chlorambucil vs. combined chlorambucilcorticosteroid therapy in chronic lymphocytic leukemia. Cancer. 1973;31(3):502-508.
4. Knospe WH, Loeb V. Biweekly chlorambucil treatment of lymphocytic lymphoma. Cancer Clinical Trials. 1980;3(4):329-336.
5. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107(3):885-891.
6. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007;25(7):793-798.
7. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet. 2007;370 (9583):230-239.
8. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376 (9747):1164-1174.
9. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105 (1):49-53.
10. Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progressionfree survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1756-1765.
11. Tam CS, O'Brien S, Wierda W, et al. Longterm results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112(4):975-980.
12. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101-1110.
13. Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M; ESMO Guidelines Working Group. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow- up. Ann Oncol. 2011;22 (Suppl 6):vi50-54.
14. Bosch F, Ferrer A, Lopez-Guillermo A, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol. 2002;119(4):976-984.
15. Tonino SH, Gelder MV, Eldering E, Oers MHJ, Kater AP. R-DHAP is effective in fludarabine- refractory CLL, possibly via upregulation of pro-apoptotic P73. Blood (ASH Annual Meeting Abstracts). 2009; 3449.
16. Robak T, Blonski JZ, Kasznicki M, Gora- Tybor J, Dmoszynska A, Skotnicki A. The effect of subsequent therapies in patients with chronic lymphocytic leukemia previously treated with prednisone and either cladribine or chlorambucil. Haematologica. 2005;90(7):994-996.
17. Langerbeins P, Busch R, Anheier N, et al. Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. Am J Hematol. 2014;89(12):E239-243.
18. Fornecker LM, Aurran-Schleinitz T, Michallet AS, et al. Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience. Am J Hematol. 2015;90(6):511-514.
19. Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29(26):3559-3566.
20. Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30(26):3209-3216.
21. Elter T, James R, Busch R, et al. Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary highrisk, relapsed or refractory chronic lymphocytic leukemia. Leukemia. 2012;26(12):2549-2552.
22. Terasawa T, Trikalinos NA, Djulbegovic B, Trikalinos TA. Comparative efficacy of firstline therapies for advanced-stage chronic lymphocytic leukemia: a multiple-treatment meta-analysis. Cancer Treat Rev. 2013;39(4): 340-349.
23. Cheng MM, Goulart B, Veenstra DL, Blough DK, Devine EB. A network meta-analysis of therapies for previously untreated chronic lymphocytic leukemia. Cancer Treat Rev. 2012;38(8):1004-1011.
24. Tam CS, O'Brien S, Plunkett W, et al. Longterm results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood. 2014;124(20):3059-3064.
25. Bauer K, Rancea M, Roloff V, et al. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. Cochrane Database Syst Rev. 2012;11:CD008079.
26. Goede V, Engelke A, Fischer K, et al. Salvage therapy with obinutuzumab (GA101) plus chlorambucil (Clb) after treatment failure of Clb alone in patients with chronic lymphocytic leukemia (CLL) and comorbidities: results of the CLL11 study. ASH Annual Meeting Abstracts. 2014.
27. Hallek M. Signaling the end of chronic lymphocytic leukemia? New frontline treatment strategies. Blood ASH Hematology Am Soc Hematol Educ Program. 2013;138.